The global left ventricular dysfunction drug market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of heart diseases and the rising awareness about cardiovascular diseases among people. The increasing number of patients with chronic heart failure and other cardiac disorders are also driving the growth of this market. The global left ventricular dysfunction drug market by type includes BA1142524, CA1002, Carvedilol CR, CT101, Omecamtiv Mecarbil. Among these types, BA1142524 segment accounted for a major share in 2018 owing to its high efficacy and safety profile in treating heart failure symptoms such as shortness of breath and fatigue. The global left ventricular dysfunction drug market by application includes hospital and clinic applications. Hospital application segment accounted for a major share in 2018 owing to its higher adoption rate among hospitals due to their large patient population base which increases their revenue generation potentials from these drugs.
Some Of The Growth Factors Of This Market:
- The aging population is a major factor in the growth of the Left Ventricular Dysfunction Drug market.
- The increasing prevalence of cardiovascular diseases is also a major factor in the growth of the Left Ventricular Dysfunction Drug market.
- Increasing awareness about heart health and prevention is also a major factor in the growth of the Left Ventricular Dysfunction Drug market.
- Increasing incidence rates for heart failure are also a major factor in the growth of the Left Ventricular Dysfunction Drug market.
- Increasing number of people suffering from hypertension and diabetes are also factors that contribute to this market's growth.
Industry Growth Insights published a new data on “Left Ventricular Dysfunction Drug Market”. The research report is titled “Left Ventricular Dysfunction Drug Market research by Types (BAY-1142524, CAP-1002, Carvedilol CR, CTX-101, Omecamtiv Mecarbil, Others), By Applications (Hospital, Clinic, Others), By Players/Companies Bayer AG, Innopharmax Inc, Mesoblast Ltd, Novartis AG, Quantum Genomics SA, TiGenix NV”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Left Ventricular Dysfunction Drug Market Research Report
By Type
BAY-1142524, CAP-1002, Carvedilol CR, CTX-101, Omecamtiv Mecarbil, Others
By Application
Hospital, Clinic, Others
By Companies
Bayer AG, Innopharmax Inc, Mesoblast Ltd, Novartis AG, Quantum Genomics SA, TiGenix NV
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Left Ventricular Dysfunction Drug Market Report Segments:
The global Left Ventricular Dysfunction Drug market is segmented on the basis of:
Types
BAY-1142524, CAP-1002, Carvedilol CR, CTX-101, Omecamtiv Mecarbil, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer AG
- Innopharmax Inc
- Mesoblast Ltd
- Novartis AG
- Quantum Genomics SA
- TiGenix NV
Highlights of The Left Ventricular Dysfunction Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- BAY-1142524
- CAP-1002
- Carvedilol CR
- CTX-101
- Omecamtiv Mecarbil
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Left Ventricular Dysfunction Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Left ventricular dysfunction (LVD) is a condition in which the heart muscle does not work as well as it should. This can cause chest pain, shortness of breath, and fatigue. Some common drugs used to treat LVD include beta blockers (such as atenolol), ACE inhibitors (such as enalapril), and calcium channel blockers (such as nifedipine).
Some of the major companies in the left ventricular dysfunction drug market are Bayer AG, Innopharmax Inc, Mesoblast Ltd, Novartis AG, Quantum Genomics SA, TiGenix NV.
The left ventricular dysfunction drug market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Left Ventricular Dysfunction Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Left Ventricular Dysfunction Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Left Ventricular Dysfunction Drug Market - Supply Chain
4.5. Global Left Ventricular Dysfunction Drug Market Forecast
4.5.1. Left Ventricular Dysfunction Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Left Ventricular Dysfunction Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Left Ventricular Dysfunction Drug Market Absolute $ Opportunity
5. Global Left Ventricular Dysfunction Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Type
5.3.1. BAY-1142524
5.3.2. CAP-1002
5.3.3. Carvedilol CR
5.3.4. CTX-101
5.3.5. Omecamtiv Mecarbil
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Left Ventricular Dysfunction Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Left Ventricular Dysfunction Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Left Ventricular Dysfunction Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Left Ventricular Dysfunction Drug Demand Share Forecast, 2019-2026
9. North America Left Ventricular Dysfunction Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Type
9.7.1. BAY-1142524
9.7.2. CAP-1002
9.7.3. Carvedilol CR
9.7.4. CTX-101
9.7.5. Omecamtiv Mecarbil
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Left Ventricular Dysfunction Drug Demand Share Forecast, 2019-2026
10. Latin America Left Ventricular Dysfunction Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Type
10.7.1. BAY-1142524
10.7.2. CAP-1002
10.7.3. Carvedilol CR
10.7.4. CTX-101
10.7.5. Omecamtiv Mecarbil
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Left Ventricular Dysfunction Drug Demand Share Forecast, 2019-2026
11. Europe Left Ventricular Dysfunction Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Type
11.7.1. BAY-1142524
11.7.2. CAP-1002
11.7.3. Carvedilol CR
11.7.4. CTX-101
11.7.5. Omecamtiv Mecarbil
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Left Ventricular Dysfunction Drug Demand Share, 2019-2026
12. Asia Pacific Left Ventricular Dysfunction Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Type
12.7.1. BAY-1142524
12.7.2. CAP-1002
12.7.3. Carvedilol CR
12.7.4. CTX-101
12.7.5. Omecamtiv Mecarbil
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Left Ventricular Dysfunction Drug Demand Share, 2019-2026
13. Middle East & Africa Left Ventricular Dysfunction Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Left Ventricular Dysfunction Drug Market Size and Volume Forecast by Type
13.7.1. BAY-1142524
13.7.2. CAP-1002
13.7.3. Carvedilol CR
13.7.4. CTX-101
13.7.5. Omecamtiv Mecarbil
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Left Ventricular Dysfunction Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Left Ventricular Dysfunction Drug Market: Market Share Analysis
14.2. Left Ventricular Dysfunction Drug Distributors and Customers
14.3. Left Ventricular Dysfunction Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bayer AG
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Innopharmax Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Mesoblast Ltd
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis AG
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Quantum Genomics SA
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. TiGenix NV
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook